Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.  
    
.   
   Health and Clinical Management.  
    Yearb Med Inform. 2004;(1):269-271.
. 
  Item in Clipboard